Last updated 14 days ago
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
66 patients around the world
Available in United States, Brazil
Myasthenia gravis (MG) is a chronic autoimmune disease that affects the neuromuscular
junction and is characterized by muscle weakness. B cells play a role in MG, and the
disease is characterized by the presence of autoantibodies such as anti-AChR and
anti-MuSK antibodies. CD-19 target chimeric antigen receptor (CAR) T cells harness the
ability of cytotoxic T cells to directly and specifically lyse target cells to
effectively deplete both normal and autoreactive B cells in the circulation as well as
impacted lymphoid and potentially non-lymphoid tissues. KYV-101, a fully human anti-CD19
CAR T-cell therapy, will be investigated in adult subjects with myasthenia gravis (MG).
Kyverna Therapeutics
1Research sites
66Patients around the world
This study is for people with
Myasthenia gravis
Generalized myasthenia gravis
Requirements for the patient
To 75 Years
All Gender
Medical requirements
- Presence of autoantibodies to AChR or MuSK at screening.Myasthenia Gravis Foundation of America (MGFA) Class II-IV.MG-Activities of Daily Living (MG-ADL) total score of ≥6 at screening and confirmed at pre-dose baseline.QMG total score of ≥11 at screening and confirmed at pre-dose baseline.Failed treatment with 2 or more immunosuppressive/immunomodulatory therapies, or failed at least 1 immunosuppressive therapy and required chronic plasmapheresis, or IVIG (>4 times/year over ≥12 months) to control symptoms.On a stable dose of glucocorticoids and/or other immunotherapies for ≥1 month prior to screening.For patients treated with azathioprine, a stable dose for ≥2 months prior to screening is required.No change in dose of acetylcholinesterase inhibitors for ≥2 weeks prior to screening.No use of intravenous immune globulin (IVIG) or plasmapheresis (PLEX) within 4 weeks of screening or pre-dose baseline unless this is part of their SOC treatment regimen.No use of rituximab or any other anti-CD20 or CD19 monoclonal antibody within 12 weeks prior to screening.No use of FcRn inhibitors within 4 weeks prior to screening.
- Unable to washout or interrupt autoimmune disease therapy prior to apheresis.Co-occurring neurological autoimmune disease (ie, Lambert-Eaton Myasthenic Syndrome) or any disease affecting the neuromuscular junction or muscle causing weakness (eg, myositis, myopathy, motor neuropathy).History of stroke with residual sequalae and/or risk for recurrence, seizure even if well controlled on antiepileptics, neurodegenerative disease, altered mental status unexplained and/or recent/current, or uncontrolled/severe psychiatric disease.Any serious and/or uncontrolled medical condition that, in the investigator's judgment, would cause unacceptable safety risk, interfere with study procedures or results, or compromise compliance with the protocol, including but not limited to, clinically significant cardiac or pulmonary disease.History of primary immunodeficiency, organ or allogeneic bone marrow transplant, or splenectomy.Active, uncontrolled, viral, bacterial, or systemic fungal infection or recent history of repeated infections.Thymectomy <12 months of screening or planned during the study.Prior treatment with gene therapy product or cellular immunotherapy requiring vector integration and directed at any target.Patients requiring chronic anticoagulation therapy that cannot be discontinued for medical procedures.
Sites
Hospital Israelita Albert Einstein
Recruiting
SponsorKyverna Therapeutics
Study typeInterventional
Conditions
Generalized myasthenia gravis
Requirements
To 75 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06193889
